Navigation Links
Anesiva Announces New Zingo Marketing and Distribution Agreement
Date:4/29/2008

most common adverse events with Zingo were redness (erythema), red dots (petechiae) and swelling (edema). In March 2008, Anesiva submitted a supplemental new drug application (sNDA) to expand the label indication for Zingo to include adults, based on a positive Phase 3 trial in nearly 700 patients.

About Anesiva and its Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company has one FDA-approved product, Zingo(TM), for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. The second product in Anesiva's pipeline, Adlea(TM), has been shown to reduce pain after only a single administration for weeks to months in multiple settings mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain. Anesiva is based in South San Francisco, CA, USA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
2. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
3. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
4. Anesiva Appoints Daniel Janney to Board of Directors
5. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
6. Anesiva Announces Completion of Common Stock Offering
7. Anesiva Raises $45 Million in Common Stock Offering
8. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
9. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals
10. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... CA (PRWEB) May 06, 2015 ... today announced NX-Hivac, the only high vacuum AFM system ... needs for failure analysis semiconductor manufacturing. Park NX-Hivac is ... in failure analysis solutions in highly doped semiconductor processing ... required. , The high vacuum scanning spreading resistance ...
(Date:5/6/2015)... , May 6, 2015 Dr Jaspreet ... Massey University, will deliver a speech at the 2015 Asian ... the Shanghai New Expo Center.  ... introduce to attendees the topic: ,Potato Starch: A Potential ... Smart Foods., Co-editor of a 528 page ...
(Date:5/5/2015)... , May 5, 2015  Blueprint Medicines ... of its initial public offering of 9,367,708 shares ... of $18.00 per share, including shares of common ... underwriters of their option to purchase additional shares. ... to Blueprint Medicines were approximately $168.6 million, before underwriting ...
(Date:5/5/2015)... 5, 2015  23andMe, Inc., the leading personal genetics ... Research Study in collaboration with Pfizer Inc. The ... erythematosus, more commonly known as lupus, into the study ... effort is also in collaboration with the Lupus Research ... May. Approximately 1.5 million people in the ...
Breaking Biology Technology:Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3Potato Starch: A Potential Source for the Creation of Next Generation Bulk-ingredients and Smart Foods 2Blueprint Medicines Announces Closing of Initial Public Offering 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3
... 31, 2012  bioTheranostics, Inc., a bioMerieux company that ... treatment, has introduced a new product line of ... pathway interrogation called PRECIS Precision Medicine by bioTheranostics(SM). ... partners accurate diagnosis of primary tumor site and ...
... rap music can be harnessed to power a new type ... body. Acoustic waves from music, particularly rap, were found ... ultimately help to treat people stricken with aneurisms or incontinence ... a vibrating cantilever, a thin beam attached at one end ...
... The technique builds on previous research in which microbubbles were ... produce an oil which can be processed to create a ... important alternative to fossil fuels and algae, in particular, has ... now, however, there has been no cost-effective method of harvesting ...
Cached Biology Technology:bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation 2bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation 3Rap music powers rhythmic action of medical sensor 2Rap music powers rhythmic action of medical sensor 3Microbubbles provide new boost for biofuel production 2
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... CA -- Li Qian, PhD, has won the Louis ... for Young Investigators from the American Heart Association (AHA), ... that a Gladstone Institutes researcher has been the recipient. ... Gladstone -- a leading and independent biomedical-research organization -- ...
... 2011   Life Technologies Corporation (NASDAQ: ... company has introduced its GeneArt® Algae Engineering Kits, ... systems for photosynthetic microalgae Chlamydomonas reinhardtii ... model organisms for the study of photosynthesis, circadian ...
... is available in French . , MONTREAL, November ... a leukemic relapse in young patients is a step closer ... and the University of Montreal. Approximately 20 percent of young ... umbilical cord blood will experience leukemic relapse. The researchers, findings, ...
Cached Biology News:Gladstone scientist receives American Heart Association's Katz prize for cardiovascular research 2GeneArt® Algae Engineering Kits by Life Technologies™ 2GeneArt® Algae Engineering Kits by Life Technologies™ 3New hope for young leukemia patients? 2
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
B3GALT2 Immunogen: B3GALT2 (NP_003774, 324 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
... Rabbit polyclonal to ThPok ( Abpromise for ... Synthetic peptide conjugated to KLH derived from within ... (Note: the amino acid sequence is proprietary) ... .) Entrez Gene ID: ...
Biology Products: